Evaluation of Anti-neutrophil Cytoplasm Antibodies Test

Sponsor
Sohag University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04719715
Collaborator
(none)
60
1
24
2.5

Study Details

Study Description

Brief Summary

Anti-neutrophil cytoplasm antibodies (ANCA) are defined as important serological markers for the diagnosis of some forms of small vessel vasculitis, including granulomatosis with polyangiitis (GPA) , microscopic polyangiitis(MPA) and to a lesser extent Churg -Strauss syndrome or Eosinophilic granulomatosis with polyangiitis (EGPA).So they are called ANCA-associated vasculitis(AAV).

An international consensus statement for ANCA testing statement was issued in 2017 and states that the antigen specific immunoassays can be used for the accurate diagnosis of ANCA-associated vasculitis without the need for indirect immunofluorescence(IIF). In the present study we will test whether the antigen specific assays screening is a valuable alternative to IIF confirming with immunoassay for the diagnosis of AAV on a number of patients and controls.

Aim To evaluate the performance of the recommended strategy for the detection of ANCA based on screening with antigen specific immunoassays on a number of AAV patients and relevant disease controls In Kagawa university hospital (rheumatology department).

Patients and methods This is a prospective study will be conducted at the department of rheumatology in Kagawa university hospital in which consecutive samples will be included from patients suspected to have AAV; patients subsequently identified as having AAV will be included as AAV patients, while patients in which the diagnosis AAV is rejected, will be included as disease controls. PR3-and MPO-ANCA will be performed using assays from Medical & Biological Laboratories Co (Anchor CLEIA) isayama.takuya@mbl.co.jp

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Indirect immunofluorescence (IIF) , myeloperoxidase antibody(MPO)- and anti-proteinase 3 (PR3-) ANCA immunoassays

Detailed Description

To evaluate the performance of the recommended strategy for the detection of ANCA based on screening with antigen specific immunoassays on a number of AAV patients and relevant disease controls (i. e., patients for whom ANCA would be requested in the context of small-vessel vasculitis such as patients with infections, drug-induced diseases, connective tissue disease, etc.).

Study Design

Study Type:
Observational
Anticipated Enrollment :
60 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Evaluation of ANCA Testing by Antigen Specific Assays in Small Vessel Vasculitis
Anticipated Study Start Date :
Feb 1, 2021
Anticipated Primary Completion Date :
Feb 1, 2022
Anticipated Study Completion Date :
Feb 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Cases with ANCA vasculitis

Indirect immunofluorescence (IIF) will be performed as well as myeloperoxidase antibody(MPO)- and anti-proteinase 3 (PR3-) ANCA immunoassays and evaluated

Diagnostic Test: Indirect immunofluorescence (IIF) , myeloperoxidase antibody(MPO)- and anti-proteinase 3 (PR3-) ANCA immunoassays
Measurement and evaluation of the ANCA testing

Controls with autoimmune diseases other than ANCA vasculitis

Indirect immunofluorescence (IIF) will be performed as well as myeloperoxidase antibody(MPO)- and anti-proteinase 3 (PR3-) ANCA immunoassays and evaluated

Diagnostic Test: Indirect immunofluorescence (IIF) , myeloperoxidase antibody(MPO)- and anti-proteinase 3 (PR3-) ANCA immunoassays
Measurement and evaluation of the ANCA testing

Outcome Measures

Primary Outcome Measures

  1. Anti-proteinase 3 antibody (PR3), anti-myeloperoxidase (MPO) antibody presence in patients with small-vessel vasculitis versus patients without vasculitis [within two weeks of immunosuppressive treatment not after that]

    Antibodies are detected using chemiluminescent enzyme immunoassay (CLEIA).Values above 3.5 u/ml are considered positive

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

.All patients included must be older than 18 years and able to give informed consent.

  • Classification criteria and nomenclature for AAV are from the American College of Rheumatology

  • Serum sampling should be done before initiation of immunosuppressive treatment or no later than 2 weeks after onset of low-medium dose of immunosuppressive treatment (but this should be documented)

Exclusion Criteria:

.Patients younger than 18 years old

Contacts and Locations

Locations

Site City State Country Postal Code
1 Kagawa univeristy Miki Kagawa Japan 761-0793

Sponsors and Collaborators

  • Sohag University

Investigators

  • Principal Investigator: Mai Mansour, Sohag University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Mai Mahmoud Fahmy Mansour, Assistant lecturer of Rheumatology, Rehabilitation and Physical Medicine, Sohag University
ClinicalTrials.gov Identifier:
NCT04719715
Other Study ID Numbers:
  • ANCA testing evaluation
First Posted:
Jan 22, 2021
Last Update Posted:
Jan 22, 2021
Last Verified:
Jan 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Mai Mahmoud Fahmy Mansour, Assistant lecturer of Rheumatology, Rehabilitation and Physical Medicine, Sohag University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 22, 2021